Landauer Inc

Landauer — Q3 FY2016 Earnings Presentation

26 slides from Landauer's earnings presentation, Aug 9, 2016

  1. Slide 1: Investor Presentation February 2016

    Investor Presentation February 2016 2 Safe Ha

  2. Slide 2: Safe Harbor

    f the information shared here (including, in particular, the section titled “Fiscal 2016

  3. Slide 3: Forward-looking statements

    Outlook”) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and uncertainties associated with the Company’s future performance, the Company’s development and introducti

  4. Slide 4: Use of Non-GAAP Financial Measures

    directly comparable measures presented in accordance with GAAP. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is included above. Use of Non-GAAP Financial Measures

  5. Slide 5: Serving Diverse End Markets Across Three Verticals

    Serving Diverse End Markets Across Three Verticals Acute Care Professional $151 Million in FY 2015 Revenue Hospitals Onices Industrial eel Estimated U.S, Market Share - Dosimetry Acute Care J Hospitals Physician Offices Professional fil , es Gi Offices V—_ " XN Industrial 62% L re imaging Cerers 0%

  6. Slide 6: Strong Global Footprint

    Strong Global Footprint Well-positioned to serve an expanding global customer base of ~75,000 clients LANDAUER’

  7. Slide 7: Significant International Growth Opportunity

    ignificant International Growth Opportunity Estimated 25% international market share provides ample room for continued growth FYGAAP 2015 Revenue Additional $2.3 million in Equity Income from International Joint Ventures Joint Venture Location Nagase-Landauer Japan Epsilon Landauer Turkey Aquila New

  8. Slide 8: U.S. Healthcare Trends are Fueling Opportunity

    U.S. Healthcare Trends are Fueling Opportunity New Compliance Standards Tougher State Heightened Diagnostic imaging Regulations Requirements from Emerging The Joint Commission go into effect in july 2015 Healthcare Consolidation Pennsylvania Evolving Larger buying groups California Treatments create

  9. Slide 9: Uniquely Positioned to Capitalize on Demand for Solutions

    Uniquely Positioned to Capitalize on Demand for Solutions Solutions Platform Reports: Analytics: Benchmarking: Training: Continuous Necessaryfor Contextto _—Relevanceto._Assures compliance Improvement: compliance information peers and patient Integrated data outcomes across the enterprise £5 6 2 Inf

  10. Slide 10: Strategic Path Forward

    Strategic Path Forward LANDAUER’ Launch and commercialization of Verifii™ platform = Intermittent analog measurement > Connected digital platform Provide customers with timely, actionable compliance solutions Generate meaningful cost benefits Shift the market focus * Simple dose focus > Continuous m

  11. Slide 11: Verifii: Redefining Our Core Technology

    Verifii™: Redefining Our Core Technology A truly differentiated product and platform for incremental growth wrifii = Provides customers with a scalable, digital platform that connects employees to their environment * Eliminates fragmented manual processes enabling focus on building a robust radiatio

  12. Slide 12: Creating a New Standard with Digital Dosimetry

    Creating a New Standard with Digital Dosimetry ~30 million incidents measured annually (-1% physically handled) Real-time and historcaatee Va analytics are ‘ availableto ay client viaweb & mobile apps Ay Dats is processed and stored in the cloud custody Allows customers to track trends, monitor even

  13. Slide 13: Significant Opportunities Across Core Verticals

    Significant Opportunities Across Core Verticals ~ = Allows customers to outsource compliance and safety solution to Landauer at a lower cost = 74% estimated U.S. market share = Consulting forcein place to meet demand from Joint Commission requirements * Expand productline to include software, consul

  14. Slide 14: Strong Recurring Revenue Base

    Strong Recurring Revenue Base Revenue (Sin millions, FYE 9/30) si60 $152 $150 S155 $151 $20 2012 2013 2014 2015, ‘m Recurring Revenue im Non-Recurring Revenue LANDAUER’ “

  15. Slide 15: Balanced Approach to Capital Allocation

    Balanced Approach to Capital Allocation Currently 3% dividend yield = Long history of paying competitive dividend for over 20 years = Core business investments focused on top and bottom line growth + Emphasis on higher margin, annuity-style opportunities = Commercialization of next generation digita

  16. Slide 16: Compelling Investment Opportunity

    Compelling Investment Opportunity + Industry-leading technology; proprietary Optically Stimulated Luminescence (OSt) erystal manufacturing process + Installed based of over 73,000 customers; 1.8 million individuals served * 90% recurring revenue; 94% annual customer r + Ability to provide enterprise

  17. Slide 17: Financial Overview

  18. Slide 18: Landauer Financial Overview

    ndauer Financial Overview Revenue ($ in millions, FYE 9/30) * Approximately 90% of revenue derived from subscriptions and is recurring in nature $155.1 sient $1513 * Increase operating income at a higher growth $9 rate than revenue * Contract with U.S. Army, Reserve and National Guard to replace its

  19. Slide 19: Q3 FY16 Financial Highlights

    Q3 FY16 Financial Highlights Key Q3 FY 2016 Financial Drivers Revenue $40 $355 $379 * Revenue of $37.9 million in the third quarter of on fiscal 2016 includes impact of unfavorable FX wel aes ($0.2M) and our divested businesses ($0.9M) $96 * Military product sales were $2.5 million $30 $09 * Medical

  20. Slide 20: Q3 FY2016 and Q3 FY2015 Comparable Results

    Q3 FY2016 and Q3 FY2015 Comparable Results {$ Millions) Revenue Operating Income ($ Millions) Operating Income Non-GAAP financial measure LANDAUER’ $379 $77 $35.5 $5.1 $(0.8) $(0.1) $2.4) $(0.4) $(0.3) $(0.1) $0.8) $0.1 $02 $37.2 $oa $76 $32.3 $48

  21. Slide 21: YTD Q3 FY2016 and YTD Q3 FY2015 Comparable Results

    YTD Q3 FY2016 and YTD Q3 FY2015 Comparable Results {$ Millions) Revenue Operating Income ($ Millions) Operating Income Non-GAAP financial measure LANDAUER’ $112.5 $212 s1n12 $16.9 $(5.8) sia) $(7.3) $(2.0) $(0.3) $(0.2) $(4.0) $(1.5) $20 $108.6 $0.7 $20.7 $99.9 $144

  22. Slide 22: Q3 FY2016 and Q3 FY2015 Adjusted Results

    Q3 FY2016 and Q3 FY2015 Adjusted Results (6 Millions) Revenue $37.9 : : - $379 Net Income 973 $0.6 $0.4 ($2.7) $5.6 ‘Adjusted EBITDA* $14.0 $09 $05 ($3.9) suis {$ Millions) Revenue $35.5 : - : $35.5 Net Income $44 $04 : : $45 ‘Adjusted EBITDA* $87 $05 : : $92 + Non-GAAP financial measure LANDAUER 2

  23. Slide 23: Fiscal Year 2016 Outlook

    Fiscal Year 2016 Outlook Fiscal Year 2016 Outlook Original Impact of Updated ($ Millions) FY 2016 Divested FY 2016 Guidance | Business Guidance Revenue $150-$157 ($4.5) $145.5 -$152.5 Adjusted Netincome* $15-$18 ($0.5) $14.5-$17.5 = Update represents forecasted revenue and net income included in FY2

  24. Slide 24: Appendix

  25. Slide 25: Landauer at a Glance

    Landauer at a Glance Headquartered in Glenwood, IL industry standard OSL technology Founded in 1954 Passive measurement of wide Approximately 650 employees range of radiation from low energy X-Ray to high energy 8 global markets neutron 73,000 annual customers served; 1.8M annual individuals Davelon

  26. Slide 26: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures Management believes the disclosure of certain non-GAAP financial measures enhances investor understanding of our financial performance. Non-GAAP financial measures disclosed in this report include: Adjusted EBITDA, Adjusted Net Income, Pro Forma Revenue, Pro Forma

Landauer — Q3 FY2016 Earnings Presentation on 6ix